NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $14.80 -0.59 (-3.83%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$14.62▼$15.6350-Day Range$13.81▼$17.8652-Week Range$10.75▼$18.17Volume82,033 shsAverage Volume137,516 shsMarket Capitalization$499.63 millionP/E Ratio23.49Dividend YieldN/APrice Target$21.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Entrada Therapeutics alerts: Email Address Entrada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.3% Upside$21.50 Price TargetShort InterestBearish9.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$98,632 Sold Last QuarterProj. Earnings GrowthDecreasingFrom $0.68 to ($3.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector686th out of 910 stocksPharmaceutical Preparations Industry318th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.61% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 5.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Entrada Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for TRDA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,632.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $0.68 to ($3.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is 23.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is 23.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Entrada Therapeutics Stock (NASDAQ:TRDA)Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesSeptember 6 at 7:00 AM | globenewswire.comEntrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramAugust 28, 2024 | americanbankingnews.comOppenheimer Reiterates "Outperform" Rating for Entrada Therapeutics (NASDAQ:TRDA)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 27, 2024 | markets.businessinsider.comEntrada Therapeutics Inc (TRDA) Gets a Buy from OppenheimerAugust 18, 2024 | finance.yahoo.comForecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved DrasticallyAugust 14, 2024 | finance.yahoo.comEntrada Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)August 9, 2024 | investing.comEntrada Therapeutics (TRDA) Earnings Dates & ReportsSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 7, 2024 | finance.yahoo.comIs Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?August 6, 2024 | lse.co.ukEntrada Therapeutics Share Price (TRDA.US)June 24, 2024 | globenewswire.comEntrada Therapeutics Announces $100 Million Registered Direct OfferingJune 24, 2024 | globenewswire.comEntrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyJune 16, 2024 | seekingalpha.comEntrada Therapeutics: A Complicated TaleJune 3, 2024 | globenewswire.comEntrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 17, 2024 | finance.yahoo.comDirector Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)May 16, 2024 | globenewswire.comEntrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 8, 2024 | markets.businessinsider.comEntrada Therapeutics is about to announce earnings — here's what Wall Street expectsSee More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$21.50 High Stock Price Target$25.00 Low Stock Price Target$18.00 Potential Upside/Downside+45.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio23.49 Forward P/E Ratio21.76 P/E GrowthN/ANet Income$-6,680,000.00 Net Margins43.63% Pretax Margin46.11% Return on Equity35.16% Return on Assets20.41% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.70 Sales & Book Value Annual Sales$239.40 million Price / Sales2.09 Cash FlowN/A Price / Cash FlowN/A Book Value$11.56 per share Price / Book1.28Miscellaneous Outstanding Shares33,759,000Free Float31,200,000Market Cap$499.63 million OptionableOptionable Beta-0.24 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Comp: $968.21kMr. Nathan J. Dowden (Age 53)President & COO Comp: $694.3kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Comp: $694.3kMr. Kory James Wentworth CPA (Age 45)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHVerona PharmaNASDAQ:VRNABausch Health CompaniesNYSE:BHCApogee TherapeuticsNASDAQ:APGEGemini TherapeuticsNASDAQ:GMTXView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 2,146 shares on 8/15/2024Ownership: 0.169%Marshall Wace LLPBought 14,220 shares on 8/14/2024Ownership: 0.195%Squarepoint Ops LLCSold 8,151 shares on 8/14/2024Ownership: 0.077%Renaissance Technologies LLCBought 44,600 shares on 8/9/2024Ownership: 0.132%American Century Companies Inc.Bought 18,625 shares on 8/8/2024Ownership: 1.140%View All Insider TransactionsView All Institutional Transactions TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $15.09 at the beginning of the year. Since then, TRDA stock has decreased by 1.9% and is now trading at $14.80. View the best growth stocks for 2024 here. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) posted its quarterly earnings data on Tuesday, August, 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.90. The firm had revenue of $94.69 million for the quarter, compared to analyst estimates of $55 million. Entrada Therapeutics had a net margin of 43.63% and a trailing twelve-month return on equity of 35.16%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' top institutional shareholders include American Century Companies Inc. (1.14%), Bank of New York Mellon Corp (0.37%), Marshall Wace LLP (0.20%) and The Manufacturers Life Insurance Company (0.17%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, Natarajan Sethuraman, Kory James Wentworth, Peter S Kim, Nathan J Dowden, Nerissa Kreher and John F Crowley. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRDA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
